<DOC>
	<DOCNO>NCT02290366</DOCNO>
	<brief_summary>The standard option men low risk prostate cancer include active surveillance standard treatment option low risk disease , i.e . radical prostatectomy , external beam radiotherapy , whole gland prostate brachytherapy . The present study seek evaluate focal brachytherapy use isotope Cesium 131 treat patient low risk prostate cancer . The goal study determine biochemical disease free survival five year patient , well determine acute late urinary , bowel , sexual toxicity associate focal prostate brachytherapy use Cesium 131 . Patients eligible study men histologically confirm adenocarcinoma prostate clinical stage T1c-T2aN0M0 , Gleason score ≤3+3=6 , prostate specific antigen ( PSA ) &lt; 10 ng/ml PSA density ≤ 0.15 ng/cc , ≤ 2 core positive minimum 12 core sample . Additionally , patient must single , dominant index lesion MRI . The study phase II study . Patients follow prospectively . Dosimetry evaluate post-procedure , PSAs obtain every three month year one every six month year two year five . Urinary , bowel , sexual morbidity assess patient survey prior treatment , two week , treatment , three month interval year one six month interval year two five .</brief_summary>
	<brief_title>Prospective Evaluation Focal Brachytherapy Using Cesium-131 For Patients With Low Risk Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically confirm adenocarcinoma prostate Clinical stage T1cT2aN0M0 Gleason score &lt; = 3+3=6 prostate specific antigen ( PSA ) &lt; 10 ng/ml &lt; = 2 core positive minimum 12 core sample</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>